Valvular & structural heart diseaseSecondary analysis
Mitral Valve Repair for Degenerative Mitral Regurgitation (MR) With Moderate or Less Tricuspid Regurgitation
- Post hoc analysis of a randomised trial
- 39 sites
- echocardiographic core laboratory adjudication
Authors' conclusion
In this international trial with echocardiographic core laboratory adjudication, the rate of survival free from MV reoperation or any episode of severe MR during 2 years was 92% in patients with DMR and concomitant TV disease.
Study context
- Population
- Patients undergoing mitral valve (MV) repair for degenerative MR with concomitant tricuspid valve (TV) disease (moderate or less tricuspid regurgitation), 2016–2018eligible of 401 randomised
- Participants
- 314 patients
- Primary endpoint
- Treatment failure: all-cause mortality, recurrent severe MR or MV reoperation
- Follow-up
- 2 years
Primary result
As reported in the abstract
Death, MV reoperation or severe MR
Incidence of death, MV reoperation or severe MR
8.0% (25 of 313)
Further findings
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| Treatment failure by leaflet pathology (anterior or bileaflet vs posterior) · 2 years | 2.48 (1.09–5.68) | P = 0.03 | |
| 0.20.5125Odds ratio (log scale) |
MR at discharge
- Moderate MR
- 1.0% (3 of 307)
- Severe MR
- 0.7% (2 of 307)
All-cause mortality · 30 days
- 30-day all-cause mortality
- 1.0%
Death and MV reoperation · 2 years
- Died
- 3.5% (11 of 314)
- MV reoperation
- 2.2% (7 of 314)
Echocardiographic findings in survivors free of MV reoperation · 2 years
- Moderate MR
- 9.2% (27 of 295)
- Severe MR
- 1.4% (4 of 295)
- Mean MV gradient >5 mm Hg
- 2.5% (7 of 275)
Original publication
Mitral Valve Repair for Degenerative MR With Moderate or Less Tricuspid Regurgitation. J Am Coll Cardiol. Published 18 February 2026. doi:10.1016/j.jacc.2025.12.065
Summarised from the published abstract; every number is checked against it